Venus Remedies share price rose nearly 2 percent intraday on June 7 after the company received Good Manufacturing Practices (GMP) certification from Ukraine. Venus Remedies received the certification for Meropenem 500mg, Meropenem 1,000mg, Meropenem 2,000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg produced at its Carbapenem & Oncology production facilities at its unit in Baddi, Himachal Pradesh.
Granted by the State Service of Ukraine on Medicine and Dug Control (SMDC) after a stringent and elaborate audit, this certification is expected to pave the way for GMP certifications for Venus Remedies from European Medicines Agency and many medicines regulatory authorities of European Union (EU) member states and other countries spread across the globe, which follow the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S).
Catch all the market action on our live blog
Global expansion
This international GMP approval, the 27th for Venus Remedies, will also enable the company to expand its product portfolio globally with more marketing authorisations not only from Ukraine, which happens to be one of the largest pharmaceutical markets in the Common wealth of Independent States (CIS) with a worth of $5 billion, but other global markets as well.
At 10:54 hrs Venus Remedies was quoting at Rs 231.60, up Rs 2.80, or 1.22 percent on the BSE.
The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on 31 May, 2023 and 08 February, 2023, respectively.
Currently, it is trading 12.12 percent below its 52-week high and 59.72 percent above its 52-week low.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
